• Top in rheumatology: Inflammatory disease biosimilars, depression in patients with lupus

    9 days ago - By Healio

    In October, Boehringer Ingelheim's Cyltezo was approved by the FDA as the first interchangeable biosimilar to AbbVie's Humira.
    With pharmacists allowed to substitute Cyltezo for Humira without the need for the prescriber to alter the prescription, the issue of whether the cost of development was worth the price alongside incoming competitors was the top story in rheumatology last week.
    Another top story explored the persistent prevalence of depression in patients with lupus, despite therapies and medications for mood disorders and pain.
    Read these and
    Read more ...